Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation

Satohiro Masuda, Maki Goto, Tetsuya Kiuchi, Shinji Uemoto, Takaaki Kodawara, Hideyuki Saito, Koichi Tanaka, Ken Ichi Inui

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We evaluated levels of intestinal expression of absorptive-barrier P-glycoprotein (PGP) and cytochrome P-450 IIIA4 (CYP3A4) and immunosuppressant therapy in a patient who underwent living donor liver transplantation (LDLT) and received a second living donor liver transplant after chronic rejection of the first. PGP and CYP3A4 expression were measured using part of a Roux-en-Y limb. After the first LDLT, the concentration-dose ratio of orally administered tacrolimus was 159.8 ± 125.3 (average ± SD of 32 different days), similar to the average for 46 recipients of living donor liver transplants in our hospital (161.3 ± 88.1). However, the recipient required very large oral doses of cyclosporine (703.9 ± 385.4 mg/d, average ± SD of 13 different days) after the second LDLT. Although intestinal PGP level was increased markedly at the second LDLT, CYP3A4 level was decreased. In addition, levels of messenger RNA expression of several gene products related to the local inflammation, such as cyclooxygenase 2, interleukin-1β (IL-1β), IL-2, IL-6, IL-8, IL-10, and tumor necrosis factor-α, were increased. These results suggest that hepatic failure after LDLT, including chronic rejection and/or cholangitis, was accompanied by upregulation of intestinal PGP expression, which could depress the bioavailability of the immunosuppressant.

Original languageEnglish
Pages (from-to)1108-1113
Number of pages6
JournalLiver Transplantation
Volume9
Issue number10
DOIs
Publication statusPublished - Jan 1 2003
Externally publishedYes

Fingerprint

Enterocytes
Living Donors
P-Glycoprotein
Liver Transplantation
Cyclosporine
Biological Availability
Cytochrome P-450 CYP3A
Immunosuppressive Agents
Transplants
Cholangitis
Liver
Liver Failure
Tacrolimus
Cyclooxygenase 2
Interleukin-8
Interleukin-1
Interleukin-10
Interleukin-2
Interleukin-6
Up-Regulation

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hepatology
  • Transplantation

Cite this

Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. / Masuda, Satohiro; Goto, Maki; Kiuchi, Tetsuya; Uemoto, Shinji; Kodawara, Takaaki; Saito, Hideyuki; Tanaka, Koichi; Inui, Ken Ichi.

In: Liver Transplantation, Vol. 9, No. 10, 01.01.2003, p. 1108-1113.

Research output: Contribution to journalArticle

Masuda, Satohiro ; Goto, Maki ; Kiuchi, Tetsuya ; Uemoto, Shinji ; Kodawara, Takaaki ; Saito, Hideyuki ; Tanaka, Koichi ; Inui, Ken Ichi. / Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. In: Liver Transplantation. 2003 ; Vol. 9, No. 10. pp. 1108-1113.
@article{51424cfea9634fd19981014f4cab8711,
title = "Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation",
abstract = "We evaluated levels of intestinal expression of absorptive-barrier P-glycoprotein (PGP) and cytochrome P-450 IIIA4 (CYP3A4) and immunosuppressant therapy in a patient who underwent living donor liver transplantation (LDLT) and received a second living donor liver transplant after chronic rejection of the first. PGP and CYP3A4 expression were measured using part of a Roux-en-Y limb. After the first LDLT, the concentration-dose ratio of orally administered tacrolimus was 159.8 ± 125.3 (average ± SD of 32 different days), similar to the average for 46 recipients of living donor liver transplants in our hospital (161.3 ± 88.1). However, the recipient required very large oral doses of cyclosporine (703.9 ± 385.4 mg/d, average ± SD of 13 different days) after the second LDLT. Although intestinal PGP level was increased markedly at the second LDLT, CYP3A4 level was decreased. In addition, levels of messenger RNA expression of several gene products related to the local inflammation, such as cyclooxygenase 2, interleukin-1β (IL-1β), IL-2, IL-6, IL-8, IL-10, and tumor necrosis factor-α, were increased. These results suggest that hepatic failure after LDLT, including chronic rejection and/or cholangitis, was accompanied by upregulation of intestinal PGP expression, which could depress the bioavailability of the immunosuppressant.",
author = "Satohiro Masuda and Maki Goto and Tetsuya Kiuchi and Shinji Uemoto and Takaaki Kodawara and Hideyuki Saito and Koichi Tanaka and Inui, {Ken Ichi}",
year = "2003",
month = "1",
day = "1",
doi = "10.1053/jlts.2003.50179",
language = "English",
volume = "9",
pages = "1108--1113",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation

AU - Masuda, Satohiro

AU - Goto, Maki

AU - Kiuchi, Tetsuya

AU - Uemoto, Shinji

AU - Kodawara, Takaaki

AU - Saito, Hideyuki

AU - Tanaka, Koichi

AU - Inui, Ken Ichi

PY - 2003/1/1

Y1 - 2003/1/1

N2 - We evaluated levels of intestinal expression of absorptive-barrier P-glycoprotein (PGP) and cytochrome P-450 IIIA4 (CYP3A4) and immunosuppressant therapy in a patient who underwent living donor liver transplantation (LDLT) and received a second living donor liver transplant after chronic rejection of the first. PGP and CYP3A4 expression were measured using part of a Roux-en-Y limb. After the first LDLT, the concentration-dose ratio of orally administered tacrolimus was 159.8 ± 125.3 (average ± SD of 32 different days), similar to the average for 46 recipients of living donor liver transplants in our hospital (161.3 ± 88.1). However, the recipient required very large oral doses of cyclosporine (703.9 ± 385.4 mg/d, average ± SD of 13 different days) after the second LDLT. Although intestinal PGP level was increased markedly at the second LDLT, CYP3A4 level was decreased. In addition, levels of messenger RNA expression of several gene products related to the local inflammation, such as cyclooxygenase 2, interleukin-1β (IL-1β), IL-2, IL-6, IL-8, IL-10, and tumor necrosis factor-α, were increased. These results suggest that hepatic failure after LDLT, including chronic rejection and/or cholangitis, was accompanied by upregulation of intestinal PGP expression, which could depress the bioavailability of the immunosuppressant.

AB - We evaluated levels of intestinal expression of absorptive-barrier P-glycoprotein (PGP) and cytochrome P-450 IIIA4 (CYP3A4) and immunosuppressant therapy in a patient who underwent living donor liver transplantation (LDLT) and received a second living donor liver transplant after chronic rejection of the first. PGP and CYP3A4 expression were measured using part of a Roux-en-Y limb. After the first LDLT, the concentration-dose ratio of orally administered tacrolimus was 159.8 ± 125.3 (average ± SD of 32 different days), similar to the average for 46 recipients of living donor liver transplants in our hospital (161.3 ± 88.1). However, the recipient required very large oral doses of cyclosporine (703.9 ± 385.4 mg/d, average ± SD of 13 different days) after the second LDLT. Although intestinal PGP level was increased markedly at the second LDLT, CYP3A4 level was decreased. In addition, levels of messenger RNA expression of several gene products related to the local inflammation, such as cyclooxygenase 2, interleukin-1β (IL-1β), IL-2, IL-6, IL-8, IL-10, and tumor necrosis factor-α, were increased. These results suggest that hepatic failure after LDLT, including chronic rejection and/or cholangitis, was accompanied by upregulation of intestinal PGP expression, which could depress the bioavailability of the immunosuppressant.

UR - http://www.scopus.com/inward/record.url?scp=0142049741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142049741&partnerID=8YFLogxK

U2 - 10.1053/jlts.2003.50179

DO - 10.1053/jlts.2003.50179

M3 - Article

C2 - 14526408

AN - SCOPUS:0142049741

VL - 9

SP - 1108

EP - 1113

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 10

ER -